KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) EBIAT (2016 - 2025)

Historic EBIAT for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $481.0 million.

  • Teva Pharmaceutical Industries' EBIAT fell 8679.66% to $481.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year decrease of 2587.56%. This contributed to the annual value of $1.4 billion for FY2025, which is 2761.61% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EBIAT of $481.0 million as of Q4 2025, which was down 8679.66% from $434.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' EBIAT's 5-year high stood at $3.6 billion during Q4 2024, with a 5-year trough of -$1.3 billion in Q4 2022.
  • For the 5-year period, Teva Pharmaceutical Industries' EBIAT averaged around $94.9 million, with its median value being $70.0 million (2022).
  • Its EBIAT has fluctuated over the past 5 years, first plummeted by 123690.48% in 2022, then surged by 22730.68% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EBIAT stood at -$152.0 million in 2021, then crashed by 776.97% to -$1.3 billion in 2022, then skyrocketed by 227.31% to $1.7 billion in 2023, then soared by 114.67% to $3.6 billion in 2024, then crashed by 86.8% to $481.0 million in 2025.
  • Its EBIAT stands at $481.0 million for Q4 2025, versus $434.0 million for Q3 2025 and $283.0 million for Q2 2025.